Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort Study

被引：0

作者：

Belén Ruiz-Antorán

Aránzazu Sancho-López

Ferrán Torres

Víctor Moreno-Torres

Itziar de Pablo-López

Paulina García-López

Francisco Abad-Santos

Clara M. Rosso-Fernández

Ana Aldea-Perona

Eva Montané

Ruth M. Aparicio-Hernández

Roser Llop-Rius

Consuelo Pedrós

Paloma Gijón

Carolina Hernández-Carballo

María J. Pedrosa-Martínez

Consuelo Rodríguez-Jiménez

Guillermo Prada-Ramallal

Lourdes Cabrera-García

Josefa A. Aguilar-García

Rocío Sanjuan-Jimenez

Evelyn I. Ortiz-Barraza

Enrique Sánchez-Chica

Ana Fernández-Cruz

机构：

[1] Hospital Universitario Puerta de Hierro-Majadahonda,Clinical Pharmacology Department

[2] Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana,Medical Statistics Core Facility

[3] August Pi i Sunyer Biomedical Research Institute,Biostatistics Unit, Faculty of Medicine

[4] Hospital Clinic,Internal Medicine Department

[5] Autonomous University of Barcelona,Clinical Pharmacology Unit

[6] Hospital Universitario Puerta de Hierro-Majadahonda,Pneumology Department

[7] Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana,Clinical Pharmacology Department, Hospital Universitario de la Princesa, Instituto Teófilo Hernando, Faculty of Medicine

[8] Hospital Universitario Ramón y Cajal (IRYCIS),Unit of Clinical Pharmacology, Unit of Clinical Investigation and Clinical Trials

[9] Hospital Universitario Torrecardenas,Clinical Pharmacology Department

[10] Universidad Autónoma de Madrid (UAM),Clinical Pharmacology Department

[11] Instituto de Investigación Sanitaria la Princesa (IP),Department of Pharmacology

[12] Hospital Universitario Virgen del Rocío,Clinical Pharmacology Department

[13] Consorcio Parc Salut MarInstituto Hospital del Mar de Investigaciones Médicas (IMIM)Universidad Autónoma de Barcelona (UAB),Clinical Pharmacology Department

[14] Hospital Universitario Germans Trias i Pujol,Clinical Pharmacology Unit

[15] Therapeutics and Toxicology,Clinical Microbiology and Infectious Diseases Department

[16] Hospital Universitario Central de La Defensa Gómez Ulla,Internal Medicine Department

[17] Hospital Universitari de Bellvitge,Clinical Pharmacology Department

[18] Consorci Hospital General Universitari de València,Clinical Pharmacology Department

[19] Hospital General Universitario Gregorio Marañón,Departamento de Medicina Física y Farmacología, Facultad de Medicina

[20] Instituto de Investigación Sanitaria Gregorio Marañón,Epidemiology, Statistics and Research Methodology Unit

[21] Hospital Universitario Nuestra Señora Candelaria,Clinical Pharmacology Department

[22] Hospital Universitario Puerto Real,Internal Medicine Department

[23] Hospital Universitario de Canarias,Servicio de Farmacología Clínica

[24] Universidad de La Laguna (ULL),Internal Medicine Department

[25] Institute for Health Research Foundation (FIDIS),Infectious Diseases Unit, Internal Medicine Department

[26] Hospital Universitario Clínico San Carlos,undefined

[27] Hospital Costa del Sol Marbella,undefined

[28] UICEC IBIMA,undefined

[29] Hospital Universitario Virgen de la Victoria,undefined

[30] Hospital Universitario Ramón y Cajal (IRYCIS),undefined

[31] Hospital Universitario Puerta de Hierro-Majadahonda,undefined

[32] Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana,undefined

来源：

Infectious Diseases and Therapy | 2021年 / 10卷

关键词：

COVID-19; Mortality; SARS-CoV-2; Steroids; Tocilizumab;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：347 / 362

页数：15

共 59 条

[1]

Mehta P(2020)COVID-19: consider cytokine storm syndromes and immunosuppression Lancet (London, England). 395 1033-1034

[2]

McAuley DF(2020)The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease Autoimmun Rev 19 102537-432

[3]

Brown M(2020)Coronavirus infections and immune responses J Med Virol 92 424-10975

[4]

Sanchez E(2020)Why tocilizumab could be an effective treatment for severe COVID-19? J Transl Med. 18 164-2281

[5]

Tattersall RS(2020)Effective treatment of severe COVID-19 patients with tocilizumab Proc Natl Acad Sci USA 117 10970-55

[6]

Manson JJ(1998)Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group Stat Med 17 2265-424

[7]

McGonagle D(1983)The central role of the propensity score in observational studies for causal effects Biometrika 70 41-3107

[8]

Sharif K(2011)An introduction to propensity score methods for reducing the effects of confounding in observational studies Multivariate Behav Res 46 399-e484

[9]

O’Regan A(2009)Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples Stat Med 28 3083-2120

[10]

Bridgewood C(2020)Tocilizumab in patients with severe COVID-19: a retrospective cohort study Lancet Rheumatol 2 e474-undefined

← 1 2 3 4 5 6 →